Techniques in Gastrointestinal Endoscopy
Volume 12, Issue 2 , Pages 116-121 , April 2010

Biomarkers in Barrett's esophagus

  • Rhonda F. Souza, MD

      Affiliations

    • Departments of Medicine, VA North Texas Health Care System, University of Texas, Southwestern Medical School, Dallas, Texas
    • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
    • Corresponding Author InformationAddress reprint requests to Rhonda F. Souza, MD, Division of Gastroenterology (111B1), Dallas VA Medical Center, 4500 South Lancaster Road, Dallas, TX 75216

References 

  1. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–1081
  2. Srivastava S. Cancer biomarker discovery and development in gastrointestinal cancers: early detection research network-a collaborative approach. Gastrointest Cancer Res. 2007;1:S60–S63
  3. Sullivan PM, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–1061
  4. Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res. 2009;69:4112–4115
  5. Sato F, Jin Z, Schulmann K, et al. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One. 2008;3:e1890
  6. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95:1669–1676
  7. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071–3083
  8. Kerkhof M, Steyerberg EW, Kusters JG, et al. Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus. Cancer Biomark. 2008;4:1–10
  9. Huang Q, Yu C, Zhang X, et al. Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma. BMC Clin Pathol. 2008;8:5
  10. Rygiel AM, Milano F, Ten Kate FJ, et al. Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens. Genes Chromosomes Cancer. 2008;47:396–404
  11. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839–2848
  12. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67
  13. Fahmy M, Skacel M, Gramlich TL, et al. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol. 2004;17:588–596
  14. Wongsurawat VJ, Finley JC, Galipeau PC, et al. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation. Cancer Epidemiol Biomarkers Prev. 2006;15:509–516
  15. Cestari R, Villanacci V, Rossi E, et al. Fluorescence in situ hybridization to evaluate dysplasia in Barrett's esophagus: a pilot study. Cancer Lett. 2007;251:278–287
  16. Rygiel AM, Van Baal JW, Milano F, et al. Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer. 2007;109:1980–1988
  17. Schulmann K, Sterian A, Berki A, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene. 2005;24:4138–4148
  18. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 1988;19:166–178
  19. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–378
  20. Downs-Kelly E, Mendelin JE, Bennett AE, et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol. 2008;103:2333–2340
  21. Spechler SJ. Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol. 2005;100:927–935
  22. Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol. 2006;59:1029–1038
  23. Van Dekken H, Hop WC, Tilanus HW, et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol. 2008;130:745–753
  24. Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol. 2006;30:871–877
  25. Shi XY, Bhagwandeen B, Leong AS. p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus. Appl Immunohistochem Mol Morphol. 2008;16:447–452
  26. Hennig EE, Mikula M, Orlowska J, et al. Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus. J Mol Med. 2008;86:233–242
  27. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007;66:460–468
  28. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288
  29. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut. 2008;57:1200–1206
  30. Hage M, Siersema PD, Vissers KJ, et al. Molecular evaluation of ablative therapy of Barrett's oesophagus. J Pathol. 2005;205:57–64
  31. Hornick JL, Mino-Kenudson M, Lauwers GY, et al. Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. Am J Gastroenterol. 2008;103:38–47
  32. Dvorak K, Ramsey L, Payne CM, et al. Abnormal expression of biomarkers in incompletely ablated Barrett's esophagus. Ann Surg. 2006;244:1031–1036
  33. Prasad GA, Wang KK, Halling KC, et al. Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer. 2008;113:470–476
  34. Lopes CV, Mnif H, Pesenti C, et al. p53 and Ki-67 in Barrett's carcinoma: is there any value to predict recurrence after circumferential endoscopic mucosal resection?. Arq Gastroenterol. 2007;44:304–308
  35. Lopes CV, Pereira-Lima J, Hartmann AA. p53 immunohistochemical expression in Barrett's esophagus before and after endoscopic ablation by argon plasma coagulation. Scand J Gastroenterol. 2005;40:259–263
  36. Garewal H, Ramsey L, Sharma P, et al. Biomarker studies in reversed Barrett's esophagus. Am J Gastroenterol. 1999;94:2829–2833
  37. Prasad GA, Wang KK, Halling KC, et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology. 2008;135:370–379
  38. Christensen K, Murray JC. What genome-wide association studies can do for medicine. N Engl J Med. 2007;356:1094–1097
  39. Wiech T, Nikolopoulos E, Weis R, et al. Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. Lab Invest. 2009;89:385–397
  40. Li X, Galipeau PC, Sanchez CA, et al. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res. 2008;1:413–423
  41. Paulson TG, Maley CC, Li X, et al. Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009;15:3305–3314
  42. Hahn MA, Pfeifer GP. Methods for genome-wide analysis of DNA methylation in intestinal tumors. Mutat Res. 2009;Epub ahead of Print
  43. Selaru FM, Zou T, Xu Y, et al. Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene. 2002;21:475–478
  44. Greenawalt DM, Duong C, Smyth GK, et al. Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer. 2007;120:1914–1921
  45. Kan T, Meltzer SJ. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol. 2009;9:727–732
  46. Kan T, Sato F, Ito T, et al. The Mir-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology. 2009;136:1689–1700
  47. Maru DM, Singh RR, Hannah C, et al. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009;174:1940–1948
  48. Feber A, Xi L, Luketich JD, et al: MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 135:255-260
  49. Zhang DY, Ye F, Gao L, et al. Proteomics, Pathway Array and Signaling Network: based medicine in cancer. Cell Div. 2009;4:20
  50. Peng D, Sheta EA, Powell SM, et al. Alterations in Barrett's-related adenocarcinomas: a proteomic approach. Int J Cancer. 2008;122:1303–1310
  51. Zhao J, Chang AC, Li C, et al. Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping. Mol Cell Proteomics. 2007;6:987–999
  52. Streitz JM, Madden MT, Marimanikkuppam SS, et al. Analysis of protein expression patterns in Barrett's esophagus using MALDI mass spectrometry, in search of malignancy biomarkers. Dis Esophagus. 2005;18:170–176

 The author reports no direct financial interests that might pose a conflict of interest in connection with the submitted manuscript.

 This work was supported by the Office of Medical Research, Department of Veterans Affairs and the National Institutes of Health (R01-DK63621 and R01-CA134571).

PII: S1096-2883(10)00017-3

doi: 10.1016/j.tgie.2010.02.006

Techniques in Gastrointestinal Endoscopy
Volume 12, Issue 2 , Pages 116-121 , April 2010

Article Tools

* Image Usage & Resolution